|
Status |
Public on Jan 10, 2017 |
Title |
Novel Non-catalytic Substrate-selective p38α-specific MAPK Inhibitors with Endothelial-Stabilizing and Anti-inflammatory Activity |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
We developed a novel substrate-selective inhibitor of p38 MAPK, UM101, and compared its effects on TNF-induced gene expression by human lung microvascular endothelial cells (HMVECLs) with the prototypical p38 catalytic inhibitor, SB203580
|
|
|
Overall design |
HMVECLs were pretreated with DMSO (vehicle), UM101, or SB203580, then stimulated with TNF for 3h. Total RNA from treated cells and untreated control HMVECLs was isolated, poly(A) mRNA enriched and sequenced using the Illumina HiSeq platform.
|
|
|
Contributor(s) |
Hasday JD |
Citation(s) |
28298524 |
|
Submission date |
Jan 09, 2017 |
Last update date |
Jun 19, 2019 |
Contact name |
Theresa K Hodges |
E-mail(s) |
thodges@som.umaryland.edu
|
Organization name |
University of Maryland Baltimore
|
Department |
Institute for Genome Sciences
|
Street address |
801 W. Baltimore Street
|
City |
Baltimore |
State/province |
MD |
ZIP/Postal code |
21201 |
Country |
USA |
|
|
Platforms (1) |
GPL20301 |
Illumina HiSeq 4000 (Homo sapiens) |
|
Samples (12)
|
|
Relations |
BioProject |
PRJNA360618 |
SRA |
SRP096339 |